MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer.
Castration-resistant prostate cancer (CRPC) is a major clinical challenge for which no cure is currently available primarily because of the lack of proper understanding about appropriate molecular target(s). Previously we observed that inhibition of 5-lipoxygenase (5-Lox) activity induces apoptosis...
Main Authors: | Sivalokanathan Sarveswaran, Ritisha Ghosh, Shravan Morisetty, Jagadananda Ghosh |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4398363?pdf=render |
Similar Items
-
5-Lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates Lipid A endotoxin-induced inflammation.
by: Wen-Feng Fang, et al.
Published: (2014-01-01) -
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer
by: Scott T Tagawa, et al.
Published: (2013-08-01) -
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
by: Joelle El-Amm, et al.
Published: (2016-03-01) -
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
by: Joelle El-Amm, et al.
Published: (2016-01-01) -
Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer
by: Janet E. Brown, et al.
Published: (2010-09-01)